Description of Lunai Bioworks Inc's Business Segments
The company operates three reportable segments managed separately due to differing strategic and economic goals, technology, and marketing strategies: RENB, BioSymetrics, and RENC. RENB focuses on developing new immunotherapies for cancer treatment. BioSymetrics integrates multimodal data sources, including genomics, imaging, electronic health records, and other real-world evidence, to support biomarker discovery, therapeutic development, and precision medicine. RENC develops a predictive artificial intelligence-based diagnostic methodology aimed at earlier cancer detection. The chief executive officer serves as the chief operating decision maker, reviewing segment reports quarterly, assessing performance based on operating losses, and allocating resources accordingly. RENB and BioSymetrics operate in the United States, while RENC operates in the Netherlands. For the year ended June 30, 2025, segment operating losses were $15,530,056 for RENB, $237,880 for BioSymetrics, and $173,198,066 for RENC. Total consolidated assets were $1,907,647 for RENB, $6,109,643 for BioSymetrics, and $213,550 for RENC. The segments' accounting policies align with the company's overall policies.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
100 %